Rockwell Automation offers free software for Allen-Bradley MicroLogix controllers
Rockwell Software RSLogix Micro Starter Lite software helps streamline programming and troubleshooting for MicroLogix PLCs, reducing acquisition and installation costs
The software provides MicroLogix 1100 users with the ability to modify application programs while machinery is operating. The MicroLogix 1000 and MicroLogix 1100 controllers share a common architecture and are compatible with the Allen-Bradley PanelView family of operator interface devices. The RSLogix Micro Starter Lite programming software allows users to integrate Rockwell Automation controllers, drives and operator interface products more easily into their existing process architecture, helping reduce installation and configuration costs.
The compact, cost-effective MicroLogix 1000 controller can handle a wide variety of demanding control applications at 32 I/O or below, while using less space than a full-size controller. With online editing and a built-in 10/100 Mbps EtherNet/IP port for peer-to-peer messaging, the MicroLogix 1100 controller offers greater connectivity and application coverage to the MicroLogix controller family. Its built-in LCD screen displays controller status, I/O status and simple operator messages.
The RSLogix Micro Starter Lite software allows users of MicroLogix 1000 and MicroLogix 1100 controllers to fully maximise the efficiency and performance of their machines,' said Paul Gieschen, marketing director for Components Products at Rockwell Automation. 'The software helps our customers reduce costs and increase uptime, especially in today's global economy where innovation and efficiency are critical.'
Supporting the full family of MicroLogix controllers, RSLogix Micro programming software allows users to cost-effectively create, modify and monitor application programs. Please visit www.rockwellautomation.com/go/rslogixlite to download the free RSLogix Micro Starter Lite software. The software is available in the English and Chinese languages.
You may also like
Manufacturing
Domino demonstrates an integrated approach to next-generation coding at Interpack 2026
Read moreAt Interpack 2026, Domino Printing Sciences (Domino) will focus on the key challenges manufacturers face as variable data printing enters a new era shaped by 2D codes, intelligent automation, sustainability, and growing traceability demands. Domino specialists will be available throughout the show to highlight integrated solutions designed to work together on the factory floor – developed in collaboration with key industry partners to help to reduce complexity, risk, and operational friction for manufacturers
Trending Articles
You may also like
Manufacturing
Domino demonstrates an integrated approach to next-generation coding at Interpack 2026
At Interpack 2026, Domino Printing Sciences (Domino) will focus on the key challenges manufacturers face as variable data printing enters a new era shaped by 2D codes, intelligent automation, sustainability, and growing traceability demands. Domino specialists will be available throughout the show to highlight integrated solutions designed to work together on the factory floor – developed in collaboration with key industry partners to help to reduce complexity, risk, and operational friction for manufacturers
Manufacturing
Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target
BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Manufacturing
Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair
Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model
Manufacturing
BioNTech to cut up to 1860 jobs and end COVID vaccine production in Germany
The German biotech has announced it will cease production at its manufacturing sites in Germany and Singapore in its Q1 earnings report, cutting up to 22% of its workforce in the process as it pivots from COVID-19 vaccines to oncology